Resilia Pharmaceuticals
Resilia Pharmaceuticals is a privately held specialty pharma company that acquires and commercializes FDA-approved dermatology products. Founded in 2020 in Atlanta, it markets ECOZA, RECEDO, NEOSALUS, NEOCERA, and Solace to specialist prescribers and patients across the United States.
- Company typePrivate
- Founded2020
- HeadquartersSandy Springs, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Resilia Pharmaceuticals does
Resilia Pharmaceuticals is a privately held specialty pharmaceuticals company founded in 2020 and headquartered in Atlanta (Sandy Springs), Georgia. It operates as a dermatology-focused subsidiary of Peak Pharma Commercial Partners, applying a roll-up model in which it acquires or licenses FDA-approved therapeutics — primarily those that are clinically validated but commercially underpromoted — rather than developing novel molecules. Its marketed portfolio comprises five topical brands across dermatology and wound care: ECOZA® (econazole nitrate topical foam, 1%, antifungal), RECEDO® topical gel (scar treatment, recognized by the National Academy of Dermatology Nurse Practitioners as the #1 most prescribed scar treatment over the prior five years), NEOCERA® advanced cream, NEOSALUS® advanced cream/foam/lotion (wound and skin barrier care), and Solace® Eczema Cream (acquired via license in October 2021). The company does not disclose a proprietary technology platform; product assets and regulatory approvals are the core of its value.
Resilia monetizes these products through prescription pharmaceutical sales distributed across multiple channels: retail pharmacy wholesalers (with stated 2-day order fulfillment), the GoodRx pricing platform, Amazon Marketplace (for Solace), and — most strategically — an exclusive US distribution partnership with Mayne Pharma's DistributerRx subsidiary covering RECEDO and targeting specialist prescribers in plastic surgery and OB/GYN. Its go-to-market motion combines enterprise field sales executed through commercial partner ImpactBio, agency-of-record marketing via Excitant Healthcare Advertising, conference presence at NADNP and similar meetings, and patient-facing affordability programs (Resilia Savings Card and a Responsible Pricing Program). Customer segments are specialist healthcare prescribers (plastic surgery, OB/GYN, dermatology) and end patients, with revenue split between direct pharmaceutical product sales and structured per-prescription transaction fees from the DistributerRx partnership. Management is led by Executive Chairman Harsha Murthy (former King Pharmaceuticals, Eyetech, Konanda) and President/COO Mike Leone (former Bristol-Myers Squibb, Eyetech, Takeda).
Resilia Pharmaceuticals firmographics
Firmographics- Name
- Resilia Pharmaceuticals
- Legal name
- Resilia Pharmaceuticals, Inc.
- Website
- https://resiliapharma.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Resilia Pharmaceuticals is a privately held specialty pharma company that acquires and commercializes FDA-approved dermatology products. Founded in 2020 in Atlanta, it markets ECOZA, RECEDO, NEOSALUS, NEOCERA, and Solace to specialist prescribers and patients across the United States.
- Ownership category
- akta.pro rank
Resilia Pharmaceuticals industry classification
Industry- Product category
- Specialty Dermatology Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Dermatology Specialty Pharmaceuticals (HLAIACAL)
- akta.pro secondary industry
- Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)
Keywords
Where Resilia Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Sandy Springs
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Resilia Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Marketing or Sales, Personnel, Operations, Others
Revenue model
- Pharmaceutical Product Sales: Resilia generates revenue from the sale of FDA-approved pharmaceutical products across dermatology and specialty therapeutic areas. Products include ECOZA (econazole nitrate topical foam for fungal infections), RECEDO (topical gel for scar treatment), NEOCERA (advanced cream), and NEOSALUS (advanced cream, foam, or lotion for wound care). Revenue is derived from prescription volumes filled through retail pharmacies and specialty distributors.
- Distribution Partnership Revenue: Under the exclusive US distribution partnership with Mayne Pharma/DistributerRx for RECEDO topical gel, Resilia receives structured fixed fees per prescription filled. This represents a recurring transaction-based revenue stream tied to prescription volume through a digital prescription distribution platform.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Resilia Pharmaceuticals product offering
Product offeringCore offering
Resilia Pharmaceuticals acquires, licenses, and commercializes FDA-approved specialty dermatology therapeutics. Its portfolio includes prescription topical products for fungal infections (ECOZA), scar treatment (RECEDO), advanced wound care (NEOCERA, NEOSALUS), and eczema (Solace). Products are distributed through retail pharmacies, specialty wholesalers, and an exclusive US digital prescription distribution partnership with Mayne Pharma/DistributerRx.
Product overview
Resilia Pharmaceuticals is a privately held specialty pharmaceuticals company focused on acquiring high-value but underpromoted therapeutics as well as high-value therapeutics in late-stage development. The company's product portfolio consists of FDA-approved topical pharmaceutical products: ECOZA (econazole nitrate) Topical Foam 1% for antifungal treatment; RECEDO Topical Gel for scar treatment (the #1 most prescribed scar treatment over the past 5 years per NADNP); NEOCERA Advanced Cream; and NEOSALUS Advanced Cream, Foam, and Lotion. The company also acquired rights to commercialize Solace Eczema Cream. Resilia operates as a Peak Pharma Commercial Partners company, with products available through retail pharmacies and GoodRx.
Differentiator
Problem solved
Functional benefit
Brands
- ECOZA: ECOZA® (econazole nitrate) Topical Foam, 1% - antifungal treatment product
- RECEDO
- NEOCERA
- NEOSALUS
- Solace
Products and services
- ECOZA (econazole nitrate) Topical Foam, 1% FDA-approved antifungal topical foam containing 1% econazole nitrate, used for the topical treatment of fungal skin infections. Prescribed by dermatology and primary care providers and dispensed through retail pharmacies.
- RECEDO Topical Gel FDA-approved prescription topical gel for scar treatment. Recognized by the National Academy of Dermatology Nurse Practitioners (NADNP) as the #1 most prescribed scar treatment over the past 5 years. Targeted to specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.
- NEOCERA Advanced Cream NEOCERA is an FDA-approved advanced cream dermatology/skincare product within Resilia's portfolio, intended for prescription dermatological use.
- NEOSALUS Advanced Cream, Foam, or Lotion NEOSALUS is an FDA-approved advanced cream, foam, or lotion formulation for prescription dermatological and wound care use. The cream and lotion forms were relaunched in May 2023.
- Solace Eczema Cream Solace Eczema Cream is an eczema treatment product licensed for commercialization by Resilia Pharmaceuticals. Distributed via Amazon Marketplace to expand direct-to-consumer access to the dermatology portfolio.
Quantifiable outcome
- RECEDO is the #1 most prescribed scar treatment over the past 5 years (National Academy of Dermatology Nurse Practitioners, November 2021)
Companies that use Resilia Pharmaceuticals
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Resilia Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Resilia Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and major.
- Mayne Pharma Group / DistributerRxcoreMayne Pharma Group's wholly-owned subsidiary DistributerRx secured an exclusive distribution partnership with Resilia Pharmaceuticals to distribute RECEDO topical gel across the United States. DistributerRx leverages its digital prescription distribution platform and receives structured fixed fees per prescription filled. The partnership targets expansion of RECEDO's adoption among specialist healthcare prescribers in plastic surgery and OB/GYN practices for advanced scar care.
- Peak Pharma Commercial PartnerscoreResilia is a Peak Pharma Commercial Partners company. Peak Pharma provides the commercial infrastructure, capital backing, and operational framework for Resilia's pharmaceutical business. Resilia operates as the dermatology-focused subsidiary under the Peak Pharma umbrella.
- ImpactBiomajorImpactBio was appointed as commercial partner for Resilia's dermatology product line in February 2021, supporting market access, prescriber engagement, and commercial execution for products including ECOZA, RECEDO, NEOCERA, and NEOSALUS.
- Excitant Healthcare AdvertisingmajorExcitant Healthcare Advertising was appointed as agency of record for Resilia's dermatology product line in February 2021, providing multi-channel marketing, advertising, and promotional execution support across the portfolio.
Scale indicators3 records
Recent moves2 records
Expansion highlights5 records
Resilia Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- ConvaTec: Global medical products company with a dedicated Advanced Wound Care franchise. Comparable to Resilia across advanced skin and wound care therapeutics, with a far larger commercial footprint and proprietary pipeline.
- Galderma: Global dermatology specialty pharma leader with a broad prescription and aesthetic dermatology portfolio. Overlaps directly with Resilia across dermatology therapeutics and wound care, but at much larger scale and with proprietary R&D.
- Bausch Health (Ortho Dermatologics): Large diversified pharma whose Ortho Dermatologics division is a major US prescription dermatology franchise including topical steroids, antifungals, and acne/eczema products. Competes head-on with Resilia's branded dermatology portfolio.
- Mayne Pharma Group: Australian specialty pharma with US operations across dermatology, women's health, and generics. Direct strategic partner to Resilia via DistributerRx and a broad incumbent in the same dermatology/endocrinology channels.
- Smith & Nephew (Advanced Wound Management): Global medical device and wound care company. Competes with Resilia's NEOCERA and NEOSALUS wound care/advanced skin products from a much larger, diversified advanced wound care platform.
Direct peers
- Sol-Gel Technologies: Israel/US dermatology specialty pharma developing and commercializing topical branded dermatology products. Comparable in therapeutic focus and product development approach to Resilia's branded dermatology portfolio.
- Journey Medical: Commercial-stage dermatology company that acquires and markets branded dermatology products. Runs a similar 'acquire and commercialize derisked assets' model to Resilia, with overlapping prescriber channels.
- Verrica Pharmaceuticals: Small US dermatology specialty pharma commercializing branded topical therapeutics. Similar profile to Resilia: focused dermatology portfolio, lean team, and reliance on prescriber channels for adoption.
- Aclaris Therapeutics: US clinical-stage and commercial specialty pharma focused on dermatology and immunology. Closely comparable in size, therapeutic focus, and product-acquisition model to Resilia, with branded dermatology assets in similar indications.
- Harrow Health: US specialty pharma focused on acquiring and commercializing branded ophthalmic and dermatology products. Closely mirrors Resilia's acquire-and-commercialize strategy with a similarly lean operating model.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Resilia Pharmaceuticals social profiles
Digital presenceResilia Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Resilia Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles2 records
Resilia Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Resilia Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Resilia Pharmaceuticals
What does Resilia Pharmaceuticals do?
Resilia Pharmaceuticals acquires, licenses, and commercializes FDA-approved specialty dermatology therapeutics. Its portfolio includes prescription topical products for fungal infections (ECOZA), scar treatment (RECEDO), advanced wound care (NEOCERA, NEOSALUS), and eczema (Solace). Products are distributed through retail pharmacies, specialty wholesalers, and an exclusive US digital prescription distribution partnership with Mayne Pharma/DistributerRx.
Is Resilia Pharmaceuticals a public or private company?
Resilia Pharmaceuticals is a private company. It is classified as corporate owned and is currently operating.
When was Resilia Pharmaceuticals founded?
Resilia Pharmaceuticals was founded in 2020. It employs 11 to 50 people.
Where is Resilia Pharmaceuticals based?
Resilia Pharmaceuticals is headquartered in Sandy Springs, United States, in the North America region.
How does Resilia Pharmaceuticals make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are distribution Partnership Revenue.
Who are Resilia Pharmaceuticals's main competitors?
Broad incumbents on record are ConvaTec, Galderma, Bausch Health (Ortho Dermatologics), Mayne Pharma Group and Smith & Nephew (Advanced Wound Management). Direct peers are Sol-Gel Technologies, Journey Medical, Verrica Pharmaceuticals, Aclaris Therapeutics and Harrow Health.
Does Resilia Pharmaceuticals have an API?
No public API is recorded for Resilia Pharmaceuticals.
What industry is Resilia Pharmaceuticals in?
Resilia Pharmaceuticals's product category is Specialty Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAL, Dermatology Specialty Pharmaceuticals, with a secondary code of HLAIAAAK, Dermatology & Aesthetics Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.